Xenon Pharmaceuticals XENE reported a loss of 83 cents per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 94 cents. The company had incurred a loss of ...

While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study which represents a significant milestone for Xenon ...

Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company ...

A commercial expedition is planning to take clients up the tallest mountain in the world in record time with the help of xenon gas. But some in the climbing and medical world worry whether the ...

But Britain’s toughest MP and three Special Forces pals are training to smash the world record by reaching the peak in just seven days — by inhaling controversial xenon gas. Controversially ...

Xenon Pharmaceuticals has a 12 month low of $29.20 and a 12 month high of $46.00. The stock’s 50-day moving average is $36.90 and its two-hundred day moving average is $39.43.

Prior to the ascent, he and his clients will inhale xenon gas, which he says helps with acclimatization. New perk: Easily find new routes and hidden gems, upcoming running events, and more near you.

An inert and unreactive gas may not seem like an obvious candidate for treating Alzheimer’s disease, yet a new study in mice suggests that xenon might just be the breakthrough we need.

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies. Inhalation of xenon gas shows ...

Could inhaling xenon gas help fight Alzheimer’s disease? In the January 15 Science Translational Medicine, scientists led by Oleg Butovsky at Brigham and Women’s Hospital, Boston, and David Holtzman ...

The study found that Xenon gas inhalation suppressed neuroinflammation, reduced brain atrophy, and increased protective neuronal states in mouse models of Alzheimer’s disease. Results are published in ...